A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Completed
Boston Biomedical, Inc
Phase 1
2014-08-01
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered
in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU
and leucovorin.
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Completed
Sumitomo Dainippon Pharma Oncology, Inc
Phase 1
2014-08-01
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered
in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU
and leucovorin.
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
Active, not recruiting
National Cancer Institute (NCI)
Phase 1
2016-07-15
This phase I trial studies the side effects and best dose of veliparib when given together
with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and
veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
Active, not recruiting
Merck Sharp & Dohme Corp.
Phase 2
2016-09-01
This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab
(Keytruda®) and BL8040/ Pembrolizumab in combination with liposomal irinotecan
(Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic
adenocarcinoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.